Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani
Aliyah R
AR
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Ferry
Judith A
JA
Chang
Priscilla S
PS
Abramson
Jeremy S
JS
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001856:Bone Marrow Examination; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000188:drug therapy* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000821:virology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab